Glenn J. Bubley, MD

Publications

San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC.Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.J Urol. 2
21167525
Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI.Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therap
20159814
Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP.Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone,
19887483
Joshi MD, Ahmad R, Yin L, Raina D, Rajabi H, Bubley G, Kharbanda S, Kufe D.MUC1 oncoprotein is a druggable target in human prostate cancer cells.Mol Cancer Ther. 2009 Nov;8(11):3056-65.
19887552
Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG.Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.Urology. 2009 Nov;74(5):1156-61.
19647299
Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG.Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.Clin
19737960
Bhatt RS,Bubley GJ.The challenge of herbal therapies for prostate cancer.Clin Cancer Res. 2008 Dec 1;14(23):7581-2. Review.
19047081
Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ.Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.BJU Int. 2008 Aug;102(3):358-63.
18394010
Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.BJU Int. 200
18399827
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M.Design and end points of clinical tria
18309951
Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK.A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.Cancer. 2008 Feb 1;112(3):521-6.
18085595
Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ.A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.Clin Genitourin Cancer. 2007 Jun;5(5):323-8.
17645829
Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J.Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer.Prostate. 2007 Sep 1;67(12):1354
17624927
Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK.Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.J Urol. 2007 Jun;177(6):2146-50.
17509304
Masiello D, Mohi MG, McKnight NC, Smith B, Neel BG, Balk SP, Bubley GJ.Combining an mTOR Antagonist and Receptor Tyrosine Kinase Inhibitors for the Treatment of Prostate Cancer.Cancer Biol Ther. 2007 Feb;6(2):195-201.
17218776
Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM.Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.J Clin Oncol. 2006
17135641
Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A.Prostate cancer in a transgender woman 41 years after initiation of feminization.JAMA. 2006 Nov 15;296(19):2316-7.
17105793
Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP.Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15969-74.
17043241
Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, Bubley GJ, Lu ML, Balk SP.Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.Am J Pathol. 2006 Aug;169(2):682-96.
16877366
Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ.The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.J Urol. 2006 Aug;176(2):520-5.
16813881
Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW.Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.J Clin Oncol. 2006 Jun 20;24(18):2723-8.
16782912
Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP.Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.Cancer Res. 2006 Mar 1;66(5):2815-25.
16510604
Jones GB, Crasto CF, Mathews JE, Xie L, Mitchell MO, El-Shafey A, D'Amico AV, Bubley GJ.An image contrast agent selectively activated by prostate specific antigen.Bioorg Med Chem. 2006 Jan 15;14(2):418-25.
16185875
Fu XS, Choi E, Bubley GJ, Balk SP.Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation.Prostate. 2005 May 15;63(3):215-21.
15538748
Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP.Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.Int J Cancer. 2005 Jan 20;113(3):490-8.
15455390
Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ.Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen
15289492
George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ.Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.Urology. 2004 Feb;63(2):327-32.
14972483
Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ.Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.Clin Cancer Res. 2003 Aug 15;9(9):
12960113
Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M.Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.Mol Cancer Res. 2003 Aug;1(10):707-15.
12939396
Balk SP, Ko YJ, Bubley GJ.Biology of prostate-specific antigen.J Clin Oncol. 2003 Jan 15;21(2):383-91.
12525533
Bubley GJ, Balk SP, Regan MM, Duggan S, Morrissey ME, Dewolf WC, Salgami E, Mantzoros C.Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.J Urol. 2002 Nov;168(5):2249-52.
12394769
Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP.Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.J Biol Chem. 2002 Jul 19;277(29):26321-6.
12015321
Taplin ME, Bubley GJ, Rajeshkumar B, Shuster T, Ko YJ, Morganstern DE.Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.Semin Oncol. 2001 Aug;28(4 Suppl 15)
11685726
Ko YJ, Bubley GJ.Prostate cancer in the older man.Oncology (Huntingt). 2001 Sep;15(9):1113-9, 1123-4; discussio.
11589062
Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA.Loss of IFN-gamma production by invariant NK T cells in advanced cancer.J Immunol. 2001 Oct 1;167(7):4046-50.
11564825
Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP.Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10823-8.
11535819
Bubley GJ.Is the flare phenomenon clinically significant?.Urology. 2001 Aug;58(2 Suppl 1):5-9.
11502435
Jones GB, Hynd G, Wright JM, Purohit A, Plourde GW, Huber RS, Mathews JE, Li A, Kilgore MW, Bubley GJ, Yancisin M, Brown MA.Target-directed enediynes: designed estramycins.J Org Chem. 2001 Jun 1;66(11):3688-95.
11374986
Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ.A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.
11309325
Jones GB, Mitchell MO, Weinberg JS, D'Amico AV, Bubley GJ.Towards enzyme activated antiprostatic agents.Bioorg Med Chem Lett. 2000 Sep 4;10(17):1987-9.
10987433
Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW.A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.Clin Can
10815880
Shaneyfelt T, Husein R, Bubley G, Mantzoros CS.Hormonal predictors of prostate cancer: a meta-analysis.J Clin Oncol. 2000 Feb;18(4):847-53.
10673527
Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP.Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.Cancer Res. 1999 Jun 1;59(11):2511-5.
10363963
Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP.Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.N Engl J Med. 1995 May 25;332(21):1393-8.
7723794
Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W.Detection of circulating tumor cells in men with localized prostate cancer.J Clin Oncol. 1994 Dec;12(12):2634-9.
7527455
Bubley GJ, Ashburner BP, Balk SP, Ara G, Varshaney A, Teicher BA.Identification of cis-diamminedichloroplatinum(II) adducts in DNA from drug-treated human cell nuclei.Biotechniques. 1992 May;12(5):694, 696, 698.
1515136
Bubley GJ, Chapman B, Chapman SK, Crumpacker CS, Schnipper LE.Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions.Antimicrob Agents Chemother. 1989 Jun;33(6):862-5.
2669626

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Glenn J. Bubley, MD Publications San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC.Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.J Urol. 2 21167525 Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI.Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therap 20159814 Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP.Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, 19887483 Joshi MD, Ahmad R, Yin L, Raina D, Rajabi H, Bubley G, Kharbanda S, Kufe D.MUC1 oncoprotein is a druggable target in human prostate cancer cells.Mol Cancer Ther. 2009 Nov;8(11):3056-65. 19887552 Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG.Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.Urology. 2009 Nov;74(5):1156-61. 19647299 Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG.Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.Clin 19737960 Bhatt RS,Bubley GJ.The challenge of herbal therapies for prostate cancer.Clin Cancer Res. 2008 Dec 1;14(23):7581-2. Review. 19047081 Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ.Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.BJU Int. 2008 Aug;102(3):358-63. 18394010 Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.BJU Int. 200 18399827 Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M.Design and end points of clinical tria 18309951 Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK.A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.Cancer. 2008 Feb 1;112(3):521-6. 18085595 Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ.A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.Clin Genitourin Cancer. 2007 Jun;5(5):323-8. 17645829 Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J.Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer.Prostate. 2007 Sep 1;67(12):1354 17624927 Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK.Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.J Urol. 2007 Jun;177(6):2146-50. 17509304 Masiello D, Mohi MG, McKnight NC, Smith B, Neel BG, Balk SP, Bubley GJ.Combining an mTOR Antagonist and Receptor Tyrosine Kinase Inhibitors for the Treatment of Prostate Cancer.Cancer Biol Ther. 2007 Feb;6(2):195-201. 17218776 Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM.Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.J Clin Oncol. 2006 17135641 Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A.Prostate cancer in a transgender woman 41 years after initiation of feminization.JAMA. 2006 Nov 15;296(19):2316-7. 17105793 Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP.Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15969-74. 17043241 Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, Bubley GJ, Lu ML, Balk SP.Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.Am J Pathol. 2006 Aug;169(2):682-96. 16877366 Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ.The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.J Urol. 2006 Aug;176(2):520-5. 16813881 Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW.Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.J Clin Oncol. 2006 Jun 20;24(18):2723-8. 16782912 Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP.Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.Cancer Res. 2006 Mar 1;66(5):2815-25. 16510604 Jones GB, Crasto CF, Mathews JE, Xie L, Mitchell MO, El-Shafey A, D'Amico AV, Bubley GJ.An image contrast agent selectively activated by prostate specific antigen.Bioorg Med Chem. 2006 Jan 15;14(2):418-25. 16185875 Fu XS, Choi E, Bubley GJ, Balk SP.Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation.Prostate. 2005 May 15;63(3):215-21. 15538748 Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP.Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.Int J Cancer. 2005 Jan 20;113(3):490-8. 15455390 Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ.Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen 15289492 George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ.Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.Urology. 2004 Feb;63(2):327-32. 14972483 Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ.Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.Clin Cancer Res. 2003 Aug 15;9(9): 12960113 Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M.Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.Mol Cancer Res. 2003 Aug;1(10):707-15. 12939396 Balk SP, Ko YJ, Bubley GJ.Biology of prostate-specific antigen.J Clin Oncol. 2003 Jan 15;21(2):383-91. 12525533 Bubley GJ, Balk SP, Regan MM, Duggan S, Morrissey ME, Dewolf WC, Salgami E, Mantzoros C.Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.J Urol. 2002 Nov;168(5):2249-52. 12394769 Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP.Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.J Biol Chem. 2002 Jul 19;277(29):26321-6. 12015321 Taplin ME, Bubley GJ, Rajeshkumar B, Shuster T, Ko YJ, Morganstern DE.Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.Semin Oncol. 2001 Aug;28(4 Suppl 15) 11685726 Ko YJ, Bubley GJ.Prostate cancer in the older man.Oncology (Huntingt). 2001 Sep;15(9):1113-9, 1123-4; discussio. 11589062 Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA.Loss of IFN-gamma production by invariant NK T cells in advanced cancer.J Immunol. 2001 Oct 1;167(7):4046-50. 11564825 Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP.Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10823-8. 11535819 Bubley GJ.Is the flare phenomenon clinically significant?.Urology. 2001 Aug;58(2 Suppl 1):5-9. 11502435 Jones GB, Hynd G, Wright JM, Purohit A, Plourde GW, Huber RS, Mathews JE, Li A, Kilgore MW, Bubley GJ, Yancisin M, Brown MA.Target-directed enediynes: designed estramycins.J Org Chem. 2001 Jun 1;66(11):3688-95. 11374986 Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ.A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. 11309325 Jones GB, Mitchell MO, Weinberg JS, D'Amico AV, Bubley GJ.Towards enzyme activated antiprostatic agents.Bioorg Med Chem Lett. 2000 Sep 4;10(17):1987-9. 10987433 Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW.A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.Clin Can 10815880 Shaneyfelt T, Husein R, Bubley G, Mantzoros CS.Hormonal predictors of prostate cancer: a meta-analysis.J Clin Oncol. 2000 Feb;18(4):847-53. 10673527 Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP.Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.Cancer Res. 1999 Jun 1;59(11):2511-5. 10363963 Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP.Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.N Engl J Med. 1995 May 25;332(21):1393-8. 7723794 Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W.Detection of circulating tumor cells in men with localized prostate cancer.J Clin Oncol. 1994 Dec;12(12):2634-9. 7527455 Bubley GJ, Ashburner BP, Balk SP, Ara G, Varshaney A, Teicher BA.Identification of cis-diamminedichloroplatinum(II) adducts in DNA from drug-treated human cell nuclei.Biotechniques. 1992 May;12(5):694, 696, 698. 1515136 Bubley GJ, Chapman B, Chapman SK, Crumpacker CS, Schnipper LE.Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions.Antimicrob Agents Chemother. 1989 Jun;33(6):862-5. 2669626
Site Map Site Feedback Web Privacy Policy